Research programme: vaccines - Matrivax

Drug Profile

Research programme: vaccines - Matrivax

Alternative Names: Vi PCMV; Vi PCMV - Matrivax

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Matrivax
  • Class Bacterial polysaccharides; Bacterial vaccines; Meningococcal vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Clostridium-difficile-infections; Meningococcal infections; Pneumococcal infections; Typhoid

Most Recent Events

  • 07 Feb 2018 Matrivax and Vaccine Technology enter into a strategic collaboration for vaccine process development in China before February 2018 (Matrivax website, February2018)
  • 07 Feb 2018 Preclinical trials in Clostridium difficile infections (Prevention) in USA before February 2018 (Matrivax pipeline, February 2018)
  • 07 Feb 2018 Preclinical trials in Meningococcal infections (Prevention) in USA before February 2018 (Matrivax pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top